CaSR Inhibitors
1 drugsAbout CaSR
The Calcium-Sensing Receptor (CaSR) is a GPCR crucial for maintaining calcium homeostasis. Activated by changes in extracellular calcium, it triggers intracellular signaling cascades regulating physiological processes.
Currently, there is no genetic evidence directly linking CaSR to specific diseases. However, the existence of PARSABIV, an FDA-approved drug, underscores its importance as a therapeutic target.
CaSR is targeted by one FDA-approved peptide drug, PARSABIV, developed by KAI PHARMS INC. This drug addresses a therapeutic area categorized as 'other,' suggesting niche applications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis with only 1 trials.
Top Drugs
KAI PHARMS INC is the only company with an approved CaSR-targeting drug.
The market is highly concentrated, presenting a high barrier to entry unless differentiated mechanisms are pursued.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CaSR, using peptide modality.
Explore small molecule or antibody modalities to diversify the therapeutic approach and expand market potential.
Clinical Trials 37 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 14 | 13 | 0 | 1 | 100% |
| Phase 2 | 8 | 7 | 1 | 0 | 88% |
| Phase 3 | 11 | 9 | 0 | 2 | 100% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved CaSR drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CaSR. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2017 - 2017)
PARSABIV was first approved in 2017 and remains the most recent approval.
The approval timeline suggests a lack of recent innovation; new CaSR-targeting therapies could revitalize the field.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 17 clinical trials targeting CaSR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities